For foreign Emerging Stock Board enterprises, ”*- country of incorporation” indicates stocks without par value or with par value other than NT$10, and ”- country of incorporation” indicates stocks with par value of NT$10 per share.
|
|
| Basic information |
| Chairman |
President |
Spokesperson |
Telephone |
Address |
ESM Registration Date |
| HSU, HUAN-CHING |
Yachun Wang |
Yachun Wang |
02-26972628 |
24F-8, No.97, Sec. 1, Xintai 5th Rd., Xizhi DistNew Taipei City , Taiwan (R.O.C.) |
2012/05/07 |
| Industrycategory |
Key businesses |
| Biotechnology and Medical Care |
Established in 1998, TCM Biotech International Corp. is a leading biotech company in Taiwan specializing in innovative research and development of new drugs, supplements and functional ingredients. Its tremendous effort since day one has earned a lot of recognitions and awards. TCM Biotech is the second company ratified by Taiwan's Ministry of Economic Affairs to be a "Biotechnology New Drug Company" for its remarkable R&D capability and achievements. Nowadays, TCM Biotech focus on develops the new drug for prevention and treatment of liver disease, HCC (hepatocellular carcinoma) and medical device for retardation, improvement and treatment of joint disease, has expanded its territory to include distribution of western medicine, supplements and organic food. The main prospect of TCM Biotech is to provide the best health-care to the whole mankind by developing uniquely innovative techniques and products through combining wisdom and the management philosophy of reliable operation. |
| Financial data |
| Cash flows statement
| Item
|
|
|
| Amount(NTD, in thousands) |
| Cash flows from operating activities |
|
|
| Cash flows from investing activities |
|
|
| Cash flows from financing activities |
|
|
Consolidated/Individual
balance sheet
|
Current assets |
|
|
| Non-current assets |
|
|
| Total assets |
|
|
| Current liabilities |
|
|
| Non-current liabilities |
|
|
| Total liabilities |
|
|
| Share capital |
|
|
| Capital surplus |
|
|
| Retained earnings |
|
|
| Other equity interest |
|
|
| Treasury shares |
|
|
| Total equity attributable to owners of parent |
|
|
| Non-controlling interests |
|
|
| Total equity |
|
|
| Book Value per share(NT$) |
|
|
Consolidated/Individual
profit and loss
statement |
Operating revenue |
|
|
| Operating costs |
|
|
| Gross profit from operations |
|
|
| Operating expenses |
|
|
| Net other income (expenses) |
|
|
| Net operating income |
|
|
| Non-operating income and expenses |
|
|
| Profit before tax |
|
|
| Tax expense |
|
|
| Profit from continuing operations |
|
|
| Profit from discontinued operations |
|
|
| Profit |
|
|
| Other comprehensive income |
|
|
| Comprehensive income |
|
|
| Basic earnings per share |
|
|
 Auditor's report on latest financial statements： auditor's report：
|
|
Investors may find more detailed information on the company by visiting the Market Observation Post System.。
|
|
The information disclosed here concerning foreign enterprises consists of amounts provided in consolidated financial statements.
|
